Now Reading: Gland Pharma shares hit 52-week high on 58% profit jump
-
01
Gland Pharma shares hit 52-week high on 58% profit jump
The Story in Brief
Gland Pharma shares hit a 52-week high of Rs 3,352 on Monday, 9 November, rising nearly 7% despite a broader market sell-off, after the company reported a 58% jump in net profit for the September 2026 quarter. The stock touched Rs 3,345 on the NSE, according to The Economic Times, while Livemint reports the intraday high at Rs 3,352. Revenue rose 23% year-on-year to Rs 1,834 crore.
Livemint puts net profit at Rs 291 crore, while The Economic Times reports Rs 290.8 crore. The CDMO business contributed 45% of revenue and grew 31% year-on-year, The Economic Times reports. Livemint notes the stock has gained 93.87% year-to-date. Business Standard reports Gland Pharma was among several pharma stocks that rallied on Monday, with the Nifty Pharma index hitting a record high of 29,224.85.
No brokerage target was updated in the new sources. The stock's five-year return remains negative at an 8.26% decline, Livemint notes.
Indian Opinion Analysis
Livemint, The Economic Times and Business Standard all report Gland Pharma's Q2 results from the same company release, giving near-identical revenue, profit and margin figures. Livemint leads with the 52-week high and the 93% YTD gain, while The Economic Times emphasises segment-level detail, such as CDMO's 45% revenue share and the 11 ANDA filings. Business Standard places Gland's move within a broader pharma-sector rally, noting the Nifty Pharma index record. Livemint's framing of 'defying the market sell-off' adds a contrarian angle missing from the other two. The uniform financial numbers confirm consensus, but the different lead facts show each outlet chose a distinct narrative hook. The next tangible item is whether the stock sustains its rally after the 93% YTD gain, as Livemint's headline already questions.
Coverage: 3 sources, 3 neutral
Sources (3): livemint.com (neutral report), economictimes.indiatimes.com (neutral report), business-standard.com (neutral report)
This brief was synthesised by AI from the 3 sources linked above, so one read covers every framing they carry. Methodology and corrections.
Update, 9 November 2026: this story now draws on 3 sources.
